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0.7  8 1 SDS at 1 year, +1.1  8 0.9 SDS at 2 years and +1.8  8 
1.2 SDS at 4 years. At diagnosis, mean chronological age was 
4.4  8 1.6 years and height SDS was 2  8 1.7. Bone age was 
accelerated (9.4  8 4 years) at diagnosis. Signs that had led to 
diagnosis were pubic hair (n = 11), accelerated growth rate
(n = 6) and birth of an affected sister (n = 3). Despite late start 
of hydrocortisone treatment, mean final height was –1  8 0.9 
SDS. Seven of 18 patients had a final height within 1 SD of 
target height.  Conclusion: Height velocity is not markedly 
increased in untreated boys with simple virilizing CAH in the 
first 6 months of life, indicating that infants are relatively an-
drogen insensitive during that period. After the first 6
months of life, growth velocity increases significantly and el-
evated androgens lead to advanced skeletal maturation. 
This observation has implications for lower hydrocortisone 
doses to be used in CAH children during the first 6 months 
of life. In addition, staying alert for clinical symptoms and 
signs of simple virilizing CAH is still warranted, since mild 
forms may be missed in newborn screening. 
 Copyright © 2010 S. Karger AG, Basel 
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 Abstract 
 Context: Mild forms of simple virilizing congenital adrenal 
hyperplasia (CAH) may be missed in newborn screening. In 
the pre-newborn-screening era, missed diagnosis of simple 
virilizing CAH was not infrequent in boys. Elevated adrenal 
androgens lead to accelerated growth and bone maturation. 
Traditional treatment of CAH consists of the suppression of 
ACTH through glucocorticoid replacement, in an attempt to 
reduce excessive androgen production.  Objective: To retro-
spectively analyze early growth pattern and bone matura-
tion in untreated boys with simple virilizing CAH.  Patients: 
In the pre-newborn screening era, 13 boys had a late diag-
nosis of simple virilizing classical CAH. Diagnosis of 21-hy-
droxylase deficiency was confirmed by mutation analysis of 
the  CYP21A2  gene in all patients. Growth data were retro-
spectively collected from standarized preventive medical 
checkups at the regular pediatrician until the time of diagno-
sis of CAH.  Results: Length was 0.1  8 0.8 SDS (mean  8 SD) 
at birth, 0.2  8 1 SDS at 3 months, 0.2  8 0.9 SDS at 6 months, 
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 Introduction 
 Congenital adrenal hyperplasia (CAH) is caused by 
the loss or severe decrease in activity in 1 of the 5 ste-
roidogenic enzymes involved in cortisol biosynthesis. 
21-Hydroxylase deficiency is found in over 90% of all cas-
es  [1] . It is caused by mutations in the 21-hydroxylase gene 
 CYP21A2 , which is located in the human leukocyte anti-
gen (HLA) gene cluster region on the short arm of chro-
mosome 6 (6p21.3)  [2] . The disease is divided on clinical 
criteria into the classical and the nonclassical forms. The 
worldwide incidence of classical 21-hydroxylase deficien-
cy is approximately 1 in 14,000 births  [3] . Therefore, car-
rier frequency of this autosomal-recessive disease is about 
1 in 60. The deficiency of 21-hydroxylase leads to accu-
mulation of 17-hydroxyprogesterone and results in in-
creased production of adrenal androgens, and decreased 
production of cortisol. In addition to impaired cortisol 
biosynthesis, aldosterone production may be decreased 
as well (salt-wasting CAH).
 In simple virilizing CAH there is virilization of exter-
nal genitalia in newborn females, and pseudoprecocious 
puberty due to overproduction of androgens in both sex-
es. In salt-wasting CAH, additional severe renal salt loss 
occurs as a consequence of aldosterone deficiency.
 Overproduction of androgens causes virilization, ac-
celerated growth, advanced skeletal maturation, and ear-
ly epiphyseal fusion. Whereas the various forms of CAH 
differ in their degree of enzymatic deficiency, they all 
represent a therapeutic challenge to pediatric endocrinol-
ogists attempting to optimize growth. 
 Nowadays diagnosis of classical CAH is no longer de-
layed in industrialized countries, since newborn screen-
ing is available, but mild forms of simple virilizing CAH 
may be missed in newborn screening  [4] .
 Traditional treatment of CAH consists of the suppres-
sion of ACTH through glucocorticoid replacement in an 
attempt to reduce excessive androgen production and its 
consequences. Parsimonious treatment with glucocorti-
coids may result in androgen excess with advancement of 
bone age, and a reduced final height. In overtreatment, 
growth is suppressed by the growth-inhibiting effects of 
glucocorticoids. Further side effects of overtreatment are 
truncal obesity and osteoporosis. According to the con-
sensus statement of the Lawson Wilkins Pediatric Endo-
crine Society and the European Society of Pediatric En-
docrinology, typical hydrocortisone doses range from 10 
to 15 mg hydrocortisone per m 2 per day, but higher doses 
up to 25 mg per m 2 per day are believed to be necessary 
initially  [5] . Alternate approaches to the treatment of 
CAH have been investigated recently, including the use 
of antiandrogens, aromatase inhibitors, and adrenalec-
tomy  [6] . However, the mainstay of therapy remains judi-
cious glucocorticoid treatment along with careful moni-
toring of growth velocity, skeletal maturation and moni-
toring of urine, serum and salivary steroid hormone 
levels  [7] .
 In this paper, we report on the growth pattern of 13 
male patients with delayed diagnosis of simple virilizing 
CAH.
 Patients and Methods 
 In the pre-newborn screening era 13 boys were belatedly di-
agnosed with simple virilizing CAH. Growth data were collected 
retrospectively from standardized medical check-ups at their 
regular pediatrician at 3, 6, 12, 24, 48 and 60 months of age. Pa-
tients were diagnosed clinically by symptoms and signs of pseu-
doprecocious puberty, accelerated growth, or birth of an affected 
sister. Diagnosis of CAH was reconfirmed by comprehensive ge-
notyping  [8] later in all patients (deletion of one gene and muta-
tion of a second gene n = 4, compound heterozygous mutations 
n = 9). Two patients had the P30L mutation, which usually pres-
ents with a non-classic CAH phenotype. However, these 2 pa-
tients presented with the clinical picture of simple virilizing 
CAH. After the diagnosis of CAH was established, all patients 
were treated with hydrocortisone three times daily with doses 
between 12 and 20 mg/m 2 body surface area per day. All patients 
were followed until they reached adult height. Height standard 
deviation scores (H-SDS) were calculated with a growth calcula-
tor, using reference data from Prader et al.  [9] , which is used in 
the ‘Alpine’ region (Switzerland, Austria, southern Germany). 
Body mass index (BMI) was calculated as weight [kg]/height 
[m] 2 and BMI-SDS was derived from data published by Cole et 
al.  [10] . 
 Bone age was assessed by X-ray of the left hand using the 
Greulich and Pyle method  [11] . Bone age was read by both an ex-
perienced pediatric endocrinologist and a radiologist.
 Statistical analyses were performed with the nonparametric 
Wilcoxon test and correlation was assessed by the nonparametric 
Spearman-Rho method. Statistical analyses were done with the 
SPSS 15.0 software, SPSS Inc., Chicago, Ill., USA 2002. p  ! 0.05 
was considered statistically significant. 
 Results 
 Birth length corrected for gestational age was average 
in all boys with delayed diagnosis of CAH (mean birth 
length 0.1  8 0.8 SDS, median 0.1 SDS).  Table 1 shows 
data on mutation analysis, clinical presentation, height 
SDS and bone age at the time of diagnosis. Signs that had 
led to diagnosis of CAH were pubic hair (n = 11), acceler-
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ated growth rate (n = 6) and birth of an affected sister
(n = 3). At diagnosis, mean chronological age of the 13 
boys was 4.4  8 1.6 years (median 4.6 years) and H-SDS 
was +2  8 1.7 SDS (median 2.5 SDS) and bone age was 
significantly accelerated [9.4 8 4 years (median 10 years)]. 
A positive linear correlation between age at diagnosis and 
bone age acceleration was found (r = 0.7, p  ! 0.05) ( fig. 1 ). 
The growth pattern of these boys with delayed diagnosis 
of simple virilizing CAH is shown in  figure 2 : at birth
(n = 13) length was 0.1  8 0.8 SDS (mean  8 SD), at 3 
months (n = 13) 0.2  8 1 SDS, at 6 months (n = 13) 0.2  8 
0.9 SDS, at 1 year (n = 13) 0.7  8 1 SDS, at 2 years (n = 9) 
+1.1  8 0.9 SDS and at 4 years (n = 8) +1.8  8 1.2 SDS. Ac-
cordingly, mean height SDS increased by 0.1 SDS during 
the first 6 months (p  1 0.05), by 0.5 SDS between 6 and 
12 months (p  ! 0.05), by 0.4 SDS in the second year (p  ! 
0.05), and by 0.7 SDS between the ages of 2 and 4 years
(p  ! 0.05). 
 BMI-SDS did not change significantly during the first 
4 years of life (BMI-SDS at 1 year –0.7  8 1 [median –0.6], 
at 2 years –0.4  8 0.9 [median –0.7] and at 4 years –0.4  8 
1 [median –0.2].
 Despite late start of conventional hydrocortisone 
treatment with doses between 12 and 20 mg/m 2 body sur-
face area, mean final height (adult height) was –1  8 0.9 
SDS. Mean corrected final height (final height-target 
height) was –1  8 0.8 SDS (median –0.8 SDS) and 7 of 13 
patients reached a final height within 1 SD of parental 
target height. 
 Discussion 
 In this small but well-documented cohort of belatedly 
diagnosed boys with simple virilizing CAH, growth dur-
ing the first 6 months of life was not accelerated in the 
Table 1. M utation analysis, clinical presentation, height and bone age at diagnosis
Pa-
tient
No.
M utation analysis Clinical presentation Age
at Dx
years
Height
at Dx
(SDS)
Bone age
at Dx
years
Final height
(adult height)
(SDS)
FH-TH 
(SDS) allele 1 allele 2
1 complete deletion P30L pubic hair, genital status 6.8 1.4 11 –1 –0.8
2 Intron 2 I172N pubic hair, genital status, growth spurt 1.3 2.8 2 0.8 –0.5
3 complete deletion P30L pubic hair, genital status 6.3 1.5 10 –0.7 0.4
4 Intron 2 I172N birth of sister with CAH, growth spurt 4.1 2.2 7 –0.2 –0.6
5 I172N I172N pubic hair, genital status, growth spurt 2.6 1.6 5.5 –2.2 –0.8
6 I172N I172N pubic hair, genital status, growth spurt 3.6 3 11.5 –0.9 –1.6
7 Intron 2 Intron 2 pubic hair, genital status 2.8 0.3 6 –1.2 –0.8
8 complete deletion I172N pubic hair, genital status, birth of sister with CAH 4 3 9 –1.5 –1.3
9 I172N I172N pubic hair, genital status, growth spurt 5 3.7 12 –1.1 –2.4
10 Intron 2 I172N pubic hair, genital status, birth of sister with CAH 5.7 3.5 10 –0.7 –1.2
11 Intron 2 I172N pubic hair, genital status 5.1 2.5 8 –1.5 –1.7
12 I172N I172N completed growth 16 –2.6 18 –2.9 –1.9
13 complete deletion I172N pubic hair, genital status, growth spurt 5 3.4 12.5 0.2 0.2
Dx = Diagnosis; FH-TH = Final height-target height = corrected final height.
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 Fig. 1. Correlation between age at diagnosis and bone age at diag-
nosis. 
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absence of glucocorticoid treatment. So far, similar ob-
servations have been published in 32 patients only  [12, 
13] . At first sight one might ask if this is a noteworthy 
finding, but we believe that this is an important observa-
tion, because it points out that infants with early diag-
nosed CAH might not need high doses of hydrocortisone 
during the first 6–12 months of age and that suboptimal 
hormonal control could be tolerated at that age. Initial 
treatment with higher doses of up to 25 mg hydrocorti-
sone per m 2 per day, as suggested by the consensus state-
ment of the LWPES and the ESPE  [5] , might have long-
term deleterious effects on growth and metabolism and 
may not be necessary. Our experience is that hydrocorti-
sone doses at the lower end of the consensus statement 
recommendation are sufficient for normal linear growth 
and avoidance of adrenal crisis, if hydrocortisone doses 
are duplicated during illness and acute stress.  
 Thilén et al. [12] report that early growth is not in-
creased in 14 untreated Swedish children with moder-
ately severe 21-hydroxylase deficiency during the first 18 
months of age. They also report on one British 4-month-
old female infant that was diagnosed with simple viriliz-
ing CAH, whose parents refused glucocorticoid treat-
ment until the age of 4 years. That girl was prospectively 
followed, and until the age of 18 months, growth was lin-
ear and bone age was not accelerated despite high concen-
trations of plasma androgens.
 In a Dutch study of 17 untreated patients with late di-
agnosis of simple virilizing CAH, a similar growth pat-
tern was observed  [13] . Until the age of 12 months, growth 
velocity was not accelerated. But after 1 year of age, 
growth velocity increased significantly.
 This observation suggests that the androgen excess is 
either relatively moderate during the first year of life or 
that the androgen sensitivity changes after the first year 
of life.
 The thesis of relative androgen insensitivity of infants 
can also be supported by the observation of linear growth 
of infants during the minipuberty of infancy. During the 
first 6 months of age in boys and during the first 12 
months of age in girls, sex hormones may reach pubertal 
concentrations. Nevertheless, infants show normal linear 
growth and regular advancement of bone age  [14] . 
 In our cohort, birth length was average in boys with 
classical CAH. In contrast, significantly increased birth 
length was observed in an Italian and in a Finnish popu-
lation with classical CAH  [15, 16] . Worldwide, healthy 
males are known to be heavier than healthy females at 
term birth. This difference is at least partially explained 
by androgen action in utero  [17] .
 In the majority of our patients, the I172N mutation 
was found on the mildest disease-causing allele. This 
genotype correlates clearly with the simple virilizing 
CAH phenotype  [8] . The P30L mutation, which usually 
presents with a non-classic CAH phenotype, was present 
in 2 patients. However, these 2 patients presented with the 
clinical picture of simple virilizing CAH. Today, it is still 
important to stay alert for clinical symptoms and signs of 
simple virilizing CAH and not to rely on newborn screen-
ing alone, because mild forms (e.g. I172N genotype) may 
be missed by newborn screening  [4] . In our cohort, the 
most frequent symptoms and signs were pubic hair, en-
largement of genitalia and increased height velocity after 
the age of 6 months.
 In summary, infants with simple virilising CAH seem 
to be relatively androgen insensitive during the first 6 
months of life. This observation has implications for glu-
cocorticoid therapy of children with moderate forms of 
CAH during the first 6 months of life, especially when 
diagnosed early by newborn screening. In these children, 
treatment with conventional doses of hydrocortisone 
might result in growth suppression during the first year 
of life when growth velocity is fastest. 
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